International Journal of Drug Delivery Technology
Volume 15, Issue 2

Design and Evaluation of Tenofovir Alafenamide-Loaded Solid Lipid Nanoparticles Gel for Enhanced Transdermal Delivery

Ashish B Wadekar1*, Samir Atara1, Dipak D Kumbhar2

 1Department of Pharmaceutics, School of Pharmacy, RK University, Bhavnagar Highway, Kasturbadham, Rajkot - 360020, Gujarat, India

2Department of Pharmaceutics, K.Y.D.S.C.T’s College of Pharmacy N. H. No. 6 At / Post -Sakegaon, Tal.- Bhusawal, Dist. - Jalgaon, Maharashtra- 425201, India 

Received: 29th Apr, 2025; Revised: 15th May, 2025; Accepted: 3rd Jun, 2025; Available Online: 25th Jun, 2025 

ABSTRACT

This research essentially examines the design and evaluation of a gelling agent for transdermal delivery enhancement of Tenofovir Alafenamide (TAF)-loaded solid lipid nanoparticles (SLNs). Pre-formulation screening proved the drug is pure with a λ max 260 nm and a calibration curve (R² = 0.9999) for quantifying it. TAF-loaded SLNs showed a particle size distribution between 125.8 ± 2.0 nm to 274 ± 2.5 nm, with a PDI of 0.192 ± 0.04 to 0.214 ± 0.06 and zeta potential of -18.2 ± 4.1 mV to -26.6 ± 3.2 mV, denoting ideal characteristics for stability and drug delivery. Formulation optimization of SLN was carried out with 96.42% entrapment efficiency. The TAF-loaded SLN-gel is characterized by a homogeneous texture, adequate smoothness, and has pH values in the range of 6.02 to 6.15; during the ex-vivo permeation study, it was found that the cumulative TAF permeation over 24 h was 45.2 µg/cm². In vitro drug release data showed sustained release for 12 hours and a cumulative drug release at 71.4%. The gel showed good spreadability (7.2 cm) and extrudability (4.8-5.5 N) and minor variability over a period of 3 months. Acute dermal toxicity and skin irritation assessments were carried out and exhibited no significant side effects. The Primary Irritation Index (PII) of 0.44 classified it as a mild irritant. Therefore, it can be legitimately stated from the studies that the TAF-loaded SLN gel can be developed into a potential transdermal drug delivery system with sustained release characteristics, excellent entrapment efficiency, and good safety profiles.

Keywords: Tenofovir Alafenamide, Solid Lipid Nanoparticles, Transdermal Drug Delivery, SLN Gel, Sustained Release and Formulation Optimization.

How to cite this article: Ashish B Wadekar, Samir Atara, Dipak D Khumbhar. Design and Evaluation of Tenofovir Alafenamide-Loaded Solid Lipid Nanoparticles Gel for Enhanced Transdermal Delivery. International Journal of Drug Delivery Technology. 2025;15(2):519-30. doi: 10.25258/ijddt.15.2.20

REFERENCES

  1. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021 Sep 29;26(19):5905.https://doi.org/10.3390/molecules26195905
  2. Alkilani AZ, Nasereddin J, Hamed R, Nimrawi S, Hussein G, Abo-Zour H, Donnelly RF. Beneath the skin: a review of current trends and future prospects of transdermal drug delivery systems. Pharmaceutics. 2022 May 28;14(6):1152.https://doi.org/10.3390/pharmaceutics14061152
  3. Sabbagh F, Kim BS. Recent advances in polymeric transdermal drug delivery systems. Journal of controlled release. 2022 Jan 1;341:132-46.https://doi.org/10.1016/j.jconrel.2021.11.025
  4. Yaghmur A, Mu H. Recent advances in drug delivery applications of cubosomes, hexosomes, and solid lipid nanoparticles. ActaPharmaceuticaSinica B. 2021 Apr 1;11(4):871-85.https://doi.org/10.1016/j.apsb.2021.02.013
  5. Dhayalan M, Wang W, Riyaz SM, Dinesh RA, Shanmugam J, Irudayaraj SS, Stalin A, Giri J, Mallik S, Hu R. Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications. 3 Biotech. 2024 Feb;14(2):57. https://doi.org/10.1007/s13205-023-03901-8
  6. Di Perri G. Tenofoviralafenamide (TAF) clinical pharmacology. Le infezioni in medicina. 2021;29(4):526.https://doi.org/10.53854/liim-2904-4
  7. Wang FD, Zhou J, Li LQ, Li YJ, Wang ML, Tao YC, Zhang DM, Wang YH, Chen EQ. Improved bone and renal safety in younger tenofovirdisoproxilfumarate experienced chronic hepatitis B patients after switching to tenofoviralafenamide or entecavir. Annals of Hepatology. 2023 Sep 1;28(5):101119.https://doi.org/10.1016/j.aohep.2023.101119
  8. Fernandes LD, Lopes JR, Bonjorno AF, Prates JL, Scarim CB, Dos Santos JL. The application of prodrugs as a tool to enhance the properties of nucleoside reverse transcriptase inhibitors. Viruses. 2023 Nov 9;15(11):2234. https://doi.org/10.3390/v15112234
  9. Limenh LW. Advances in the transdermal delivery of antiretroviral drugs. SAGE Open Medicine. 2024 Jan;12:20503121231223600. https://doi.org/10.1177/20503121231223600
  10. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Frontiers in chemistry. 2021 Apr 23;9:580118.https://doi.org/10.3389/fchem.2021.580118
  11. Castro SR, Ribeiro LN, Breitkreitz MC, Guilherme VA, Rodrigues da Silva GH, Mitsutake H, Alcântara AC, Yokaichiya F, Franco MK, Clemens D, Kent B. A pre-formulation study of tetracaine loaded in optimized nanostructured lipid carriers. Scientific reports. 2021 Nov 2;11(1):21463. https://doi.org/10.1038/s41598-021-99743-6
  12. Mura P, Maestrelli F, D’Ambrosio M, Luceri C, Cirri M. Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations. Pharmaceutics. 2021 Mar 24;13(4):437.https://doi.org/10.3390/pharmaceutics13040437
  13. Ananth P, Koland M. Topical delivery of fenugreek seed extract loaded solid lipid nanoparticles based hydrogels for alopecia. Journal of Pharmaceutical Research International. 2021 Aug 6;33(40A):231-41. https://doi.org/10.9734/jpri/2021/v33i40A32239
  14. Priyadarsini S, Lahoti SR. Quality by design: Optimization of letrozole solid lipid nanoparticle for breast cancer. Indian Journal of Pharmaceutical Education and Research. 2022 Oct 1;56:1013-24.https://doi.org/10.5530/ijper.56.4.182
  15. Dolatabadi S, Karimi M, Nasirizadeh S, Hatamipour M, Golmohammadzadeh S, Jaafari MR. Preparation, characterization and in vivo pharmacokinetic evaluation of curcuminoids-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). Journal of Drug Delivery Science and Technology. 2021 Apr 1;62:102352.https://doi.org/10.1016/j.jddst.2021.102352
  16. Sonawane A, Jawale G, Devhadrao N, Bansode A, Lokhande J, Kherade D, Sathe P, Deshmukh N, Dama G, Tare H. Formulation and Development of Mucoadhesive Nasal Drug Delivery of Ropinirol HCl For Brain Targeting. International Journal of Applied Pharmaceutics. 2023;15(5):325-32. https://dx.doi.org/10.22159/ijap.2023v15i5.48437
  17. Bagde A, Kouagou E, Singh M. Formulation of topical flurbiprofen solid lipid nanoparticle gel formulation using hot melt extrusion technique. AAPS PharmSciTech. 2022 Sep 16;23(7):257. https://doi.org/10.1208/s12249-022-02410-w
  18. Khan AS, Shah KU, Mohaini MA, Alsalman AJ, Hawaj MA, Alhashem YN, Ghazanfar S, Khan KA, Niazi ZR, Farid A. Tacrolimus-loaded solid lipid nanoparticle gel: Formulation development and in vitro assessment for topical applications. Gels. 2022 Feb 18;8(2):129.https://doi.org/10.3390/gels8020129
  19. ReduanMohd FH, Mohd RS, Sayuti NS, Aliyu A, Mustapha NM, Bakar MZ, Sithambaram S, Hamzah H. Evaluation of dermal toxicity study of ethanolic extract of Morinda citrifolia fruit in SpraqueDawley rats. The Thai Journal of Veterinary Medicine. 2021;51(1):101-9.https://doi.org/10.56808/2985-1130.3098
  20. Ahmad S, Patil K, Koli G, Rahman BA, Barde L, Deshpande M, Tare H. Design, Development and Characterization of Econazole loaded Nanoparticles for Topical Application. International Journal of Pharmaceutical Quality Assurance. 2023;14(2):358-362. https://doi.org/10.25258/ijpqa.14.2.20
  21. Tiwari R, Patil A, Verma R, Deva V, Suman Rudrangi SR, Bhise MR, Vinukonda A. Biofunctionalized polymeric nanoparticles for the enhanced delivery of erlotinib in cancer therapy. Journal of Biomaterials Science, Polymer Edition. 2024 Nov 13:1-26. https://doi.org/10.1080/09205063.2024.2429328